Community Medicine Book By Naveed Alam !!HOT!!
Community Medicine Book By Naveed Alam
Dr Robin Pike is Clinical Director of Thoracic Oncology and Lung Cancer at the Royal Perth Hospital and an Associate Professor at the University of Western Australia. He trained in Anatomy at Sydney University, where he was a postgraduate of the College of Medicine. He trained in Medical Oncology at the University of Pennsylvania, receiving the Master of Science in Clinical Oncology and Radiation Therapy degree. He has had the privilege of knowing and working with the late, great Nobel laureate, Sir Charles Hedley Wainwright at the University of Oxford. Robin was awarded the FW O’Brien prize, the highest honour bestowed on a researcher in the field of medical oncology. He is a Fellow of the Royal Australasian College of Physicians and holds Diplomas in Surgery (CA&P) and in Oncology and Clinical Oncology (OCCOG). He is a member of the Australian and New Zealand College of Radiologists, the Australian and New Zealand Clinical Oncology Society, the Australian Radiation Therapy Oncology Group, and the Royal Australasian College of Physicians. He is the co-editor of textbooks in radiation oncology, health oncology and lung cancer.
Dr Neil Abbass is a thoracic surgeon and research focussed palliative oncologist working across the UK and internationally. He is based at Guy’s and St Thomas’ Hospital, and is an Honorary Consultant in Thoracic Surgery at King’s College Hospital. He trained in internal medicine and oncology at Cambridge University where he completed his clinical education and became a Fellow of the Royal College of Physicians. He is also a Fellow of the Royal College of Surgeons and a full member of the Royal College of Anaesthetists and the Royal College of Pathologists. Neil has degrees in medical physics and medical biology. He is a past president of the British Thoracic Cancer Society, and a past treasurer of the Thoracic Oncology Group. His research career was previously focussed on new ways of delivering radiotherapy and in understanding the radiobiology of new drugs. Since 2009 he has focussed his research on patients with metastatic lung cancer, which has, for many patients, become a «final» disease and supported by novel agents rather than radiotherapy. In 2013 he led a trial comparing docetaxel-carboplatin versus gemcitabine-carboplatin as the first line treatment for stage IV non-small cell lung cancer. He is also interested in the use of immunotherapy with ipilimumab in combination with CT.